These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3975255)

  • 1. Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.
    Anslow JA; Balm TK; Hooper JW; Szego P; Wagner GS
    Pharmacology; 1985; 30(1):40-4. PubMed ID: 3975255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa.
    Lanza FL; Royer GL; Nelson RS
    N Engl J Med; 1980 Jul; 303(3):136-8. PubMed ID: 6966762
    [No Abstract]   [Full Text] [Related]  

  • 3. Endoscopic comparison of three aspirin preparations and placebo.
    Petroski D
    Clin Ther; 1993; 15(2):314-20. PubMed ID: 8519040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.
    Nema H; Kato M; Katsurada T; Nozaki Y; Yotsukura A; Yoshida I; Sato K; Kawai Y; Takagi Y; Okusa T; Takiguchi S; Sakurai M; Asaka M
    J Clin Gastroenterol; 2009 Feb; 43(2):130-2. PubMed ID: 18779739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.
    Lanza FL; Rack MF; Wagner GS; Balm TK
    Dig Dis Sci; 1985 Jun; 30(6):509-12. PubMed ID: 3873326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man.
    Hoftiezer JW; Silvoso GR; Burks M; Ivey KJ
    Lancet; 1980 Sep; 2(8195 pt 1):609-12. PubMed ID: 6107406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
    Kelly JP; Kaufman DW; Jurgelon JM; Sheehan J; Koff RS; Shapiro S
    Lancet; 1996 Nov; 348(9039):1413-6. PubMed ID: 8937281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions.
    Dammann HG; Burkhardt F; Wolf N
    Aliment Pharmacol Ther; 1999 Aug; 13(8):1109-14. PubMed ID: 10468689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study.
    Chowdhury A; Ganguly G; Chowdhury D; Santra A; Gupta JD; Roy T
    Indian J Gastroenterol; 2001; 20(6):227-9. PubMed ID: 11817775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy.
    Berkowitz JM; Rogenes PR; Sharp JT; Warner CW
    Arch Intern Med; 1987 Dec; 147(12):2137-9. PubMed ID: 3689065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison.
    Scheiman JM; Behler EM; Berardi RR; Elta GH
    Dig Dis Sci; 1989 Feb; 34(2):229-32. PubMed ID: 2914543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
    Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa.
    Hoftiezer JW; O'Laughlin JC; Ivey KJ
    Gut; 1982 Aug; 23(8):692-7. PubMed ID: 7095565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers.
    Blondon H; Barbier JP; Mahé I; Deverly A; Kolsky H; Bergmann JF
    Fundam Clin Pharmacol; 2000; 14(2):155-7. PubMed ID: 10796063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?
    Cole AT; Hudson N; Liew LC; Murray FE; Hawkey CJ; Heptinstall S
    Aliment Pharmacol Ther; 1999 Feb; 13(2):187-93. PubMed ID: 10102949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment.
    Morris AD; Holt SD; Silvoso GR; Hewitt J; Tatum W; Grandione J; Butt JH; Ivey KJ
    Scand J Gastroenterol Suppl; 1981; 67():131-5. PubMed ID: 6941392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
    Haastrup P; Jarbøl DE
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin.
    Hirata Y; Kataoka H; Shimura T; Mizushima T; Mizoshita T; Tanida S; Kamiya T; Joh T
    Scand J Gastroenterol; 2011 Jul; 46(7-8):803-9. PubMed ID: 21501103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits.
    Lanza FL; Kochman RL; Geis GS; Rack EM; Deysach LG
    Am J Gastroenterol; 1991 Dec; 86(12):1743-8. PubMed ID: 1962619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.